Jennifer Fijor
Nurse Practitioner · Seattle, WANPI 1194108654
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $4,000 of the $6,295 with a category attached, or 63.5%. Salix Pharmaceuticals, A Division Of Bausch Health US, LLC accounts for 64.8% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2022 at $3,297 and has fallen 88.0% since, to $395 in 2025. Among nurse practitioner clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 67 payments — averaging $93.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$4K
- AbbVie$615
- Regeneron Healthcare Solutions, Inc.$373
- Ardelyx, Inc.$264
- Medtronic$184
- E.r. Squibb & Sons, L.L.C.$125
- plus $656 from 14 others
What the payments were for
- Speaking & faculty fees$4,00064%
- Food & beverage$2,29536%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $4,078 |
| AbbVie | 19 | $615 |
| Regeneron Healthcare Solutions, Inc. | 4 | $373 |
| Ardelyx, Inc. | 2 | $264 |
| Medtronic | 1 | $184 |
| E.r. Squibb & Sons, L.L.C. | 1 | $125 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $118 |
| Amgen | 4 | $92 |
| Johnson & Johnson | 5 | $90 |
| Bristol Myers Squibb | 5 | $80 |
| Gilead | 4 | $80 |
| Nestle Healthcare Nutrition Inc. | 2 | $43 |
| AMAG Pharmaceuticals, Inc. | 1 | $31 |
| Organon | 1 | $20 |
| Tersera Therapeutics LLC | 1 | $19 |
| UCB, Inc. | 1 | $18 |
| Pfizer | 1 | $17 |
| Merck | 1 | $16 |
| Intercept Pharmaceuticals, Inc. | 1 | $16 |
| Braintree Laboratories, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,295 in reported general payments places this provider in the 95th percentile of 2,466 nurse practitioner providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 45 | $30,545 |
| MotegrityPrucalopride Succinate | 17 | $14,626 |
| MovantikNaloxegol Oxalate | 21 | $8,886 |
| Lubiprostone | 42 | $3,244 |
| CholestyramineCholestyramine (With Sugar) | 17 | $2,839 |
| Omeprazole | 159 | $2,492 |
| Sucralfate | 16 | $2,181 |
| PrevaliteCholestyramine | 12 | $915 |
| Pantoprazole Sodium | 66 | $337 |
| LoperamideLoperamide Hcl | 12 | $324 |
| Esomeprazole Magnesium | 17 | $319 |
| Famotidine | 44 | $315 |
| Ondansetron OdtOndansetron | 14 | $302 |
| Dicyclomine Hcl | 18 | $278 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 13 | $275 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $615 | $30,54545 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $118 | $14,62617 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,466 nurse practitioner providers in Washington.
Other nurse practitioner in Seattle
- Olga VoloshinaSeattle$279K
- Sandra ChristensenSeattle$244K
- Sonia GlennieSeattle$78K
- Lia Duque Estrada de BarrosSeattle$43K
- Vanessa DunleavySeattle$34K
- Lyne Schaefer AlfonseSeattle$18K
- Amy PerezSeattle$14K
- Mei Kuen Erica ToSeattle$13K
- Omeid HeidariSeattle$13K
- Cayla AlexanderSeattle$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.